Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer.
Between 1983 and 1987 25 patients with invasive bladder cancer (16 stage tumor 3 (T3) and nine stage T4) were treated with intraarterial cisplatin and concurrent radical radiation (20/25) or intraarterial cisplatin, concurrent preoperative radiation, and cystectomy (5/25). One patient died from treatment-related toxicity. Other toxicities have been what one would expect from the individual treatment modalities except for a sensory sacral root neuropathy in 11 of 24 (46%) patients. Twenty-three of 24 (96%) patients achieved a complete response (CR) and the projected actuarial 2-year survival is 90%. Only one of the 23 complete responders has had an invasive local recurrence. The excellent complete local response and survival rates achieved warrant further study of the combination of intraarterial cisplatin and radiation as a bladder-preserving strategy.
Eapen
L
L
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Ontario, Canada.
Stewart
D
D
Danjoux
C
C
Genest
P
P
Futter
N
N
Moors
D
D
Irvine
A
A
Crook
J
J
Aitken
S
S
Gerig
L
L
D000368:Aged; D000369:Aged, 80 and over; D002406:Catheterization, Peripheral / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000628:therapy*
D002945:Cisplatin